Boston, MA – April 11, 2022 – Celent, a leading research and advisory firm focused on technology for financial institutions globally, is pleased to announce that Tom Scales has rejoined Celent as the practice lead for Health. The initial focus will be on Health insurers in the US.
“I’m excited to have Tom Scales rejoin the Celent family. We are making a significant investment in our health focus, in partnership with the Health & Life Sciences practice of our parent Oliver Wyman,” commented Jamie Macgregor, CEO of Celent. “His breadth of background across both the Health and Life domains will really kickstart our efforts. With experience at both vendors and all levels of the insurance ecosystem, Tom brings a unique perspective.”
Tom Scales, who brings decades of expertise leading vendors, insurer operations and technology groups, and very large sales teams, noted that “the almost chaos in the US healthcare industry leads to so many solutions based on technology. I am excited about helping our customers navigate the waters again. We will be particularly focusing on expanding our Executive Panel with key Health technology leaders.”
Tom’s experience includes insurance technology vendors focused on the health space. He was formerly the COO and CIO for Transamerica’s Life companies. He held similar positions with Crump Insurance Services. Most recently, he was the COO and led sales and operations for insurtech start-up Health IQ.
About Celent
Celent is a research and advisory firm dedicated to helping financial institutions formulate comprehensive business and technology strategies. Celent publishes reports identifying trends and best practices in financial services technology and conducts consulting engagements for financial institutions looking to use technology to enhance existing business processes or launch new business strategies. With a team of internationally experienced analysts, Celent is uniquely positioned to offer strategic advice and market insights on a global basis. Celent is a division of the Oliver Wyman Group, which is a wholly-owned subsidiary of Marsh McLennan. [NYSE: MMC]. For more information, visit www.celent.com. Follow Celent on Twitter @Celent_Research.
Media Contact:
Nicola Segal
nsegal@celent.com
